Jakafi Oral Tablet 10Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Jakafi: Oral tablet (10mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_14981.JPG
Jakafi 10mg Tablet
Incyte Corporation
Pill Identification: INCY  |  10

What is this Medicine?

RUXOLITINIB (RUX oh LI ti nib) is used to treat myelofibrosis and polycythemia vera.

In-Depth Information

Jakafi 10mg Tablet

NDC: 508810010
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Polycythemia Vera, Myelofibrosis

Storage Information
Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F
Jakafi 10mg Tablet
Drug Image file DrugItem_14981.JPG
Incyte Corporation
Pill Identification: INCY  |  10
Shape: round
Color: white

Reported Side Effects for Jakafi 10mg Tablet

Low White Blood Cells Incidence:
<7.0%*
Severity: SEVERE
Onset: DELAYED
Itching Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Balance Problems Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Stomach Pain Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Infection Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Fluid Retention Incidence:
<8.0%*
Severity: MODERATE
Onset: DELAYED
Lightheadedness Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Bruise Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Elevated Hepatic Enzymes Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Bruise Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Red Spotted Rash Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Bruises Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Pus In Urine Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Weight Gain Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Anemia Incidence:
<45.0%*
Severity: SEVERE
Onset: DELAYED
High Blood Pressure Incidence:
<6.0%*
Severity: MODERATE
Onset: EARLY
High Cholesterol Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Headache Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Bladder Infection Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Shortness Of Breath Incidence:
3.0%*
Severity: SEVERE
Onset: EARLY
Low Platelet Count Incidence:
5.0-13.0%*
Severity: SEVERE
Onset: DELAYED
Gas Incidence:
5.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
6.0%*
Severity: MILD
Onset: EARLY
Nose Bleed Incidence:
6.0%*
Severity: MILD
Onset: DELAYED
Weakness Incidence:
7.0%*
Severity: MILD
Onset: DELAYED
Joint Pain Incidence:
7.0%*
Severity: MILD
Onset: DELAYED
Swelling Incidence:
8.0%*
Severity: MODERATE
Onset: DELAYED
Cough Incidence:
8.0%*
Severity: MILD
Onset: DELAYED
Constipation Incidence:
8.0%*
Severity: MODERATE
Onset: DELAYED
Sore Throat Incidence:
9.0%*
Severity: MILD
Onset: DELAYED
Loose Stools Incidence:
15.0%*
Severity: MILD
Onset: EARLY
Tired Incidence:
15.0%*
Severity: MILD
Onset: EARLY
High Triglycerides Incidence:
15.0%*
Severity: MODERATE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Jakafi 10mg Tablet

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Major Lifestyle Interaction
Grapefruit juice and Jakafi 10mg Tablet(Ruxolitinib)
Grapefruit juice and Ruxolitinib(Ruxolitinib)
Side effects from Ruxolitinib may get worse if you take Grapefruit juice. Do not take Ruxolitinib and Grapefruit juice together without talking to your health care provider. Discuss any new or worsening side effects with your health care provider, including lack of energy, infection, and increased bleeding or brusing.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Jakafi

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.